Facebook
X
LinkedIn
ForwardAdaptive Radiotherapy
This session delves into the clinical rationale and workflows behind adaptive radiotherapy, review existing clinical evidence supporting its use, and discuss patient selection criteria. The key current pillars of adaptive radiotherapy are reviewed, including rationales like dose escalation, toxicity reduction, margin reduction, and safe delivery of extreme hypofractionation.
Attendees will gain insights into how adaptive RT fits within the broader radiotherapy treatment paradigm, including understanding of ongoing clinical trials that may further refine treatment strategies. Additionally, the session addresses challenges such as technology selection, training and staffing, workflow optimization, and emerging future uses of this novel, but increasingly common, treatment paradigm.
Target Audience
The meeting is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, radiation therapists, radiation dosimetrists, nurses and all other health professionals involved in the field of radiation oncology.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Evaluate the rationale and clinical evidence supporting the use of adaptive RT across disease sites, including its potential impact on patient outcomes.
- Identify appropriate patient selection criteria for adaptive RT, understand its integration into clinical practice, and recognize key considerations for optimizing treatment planning and workflows.
Moderator
- Megan E. Daly, MD, University of California Irvine, Chao Family Comprehensive Cancer Center
Speaker
- Lauren Henke, MD, MS, University Hospitals/Case Western Reserve University
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.